Hsp27 regulates EGF/β-catenin mediated epithelial to mesenchymal transition in prostate cancer

International Journal of Cancer

Volumn 136, Issue 6, 2015, Pages E496-E507

  Cordonnier, Thomas ^a   Bishop, Jennifer L ^a   Shiota, Masaki ^a   Nip, Ka Mun ^a   Thaper, Daksh ^a   Vahid, Sepideh ^a   Heroux, Devon ^a   Gleave, Martin ^a   Zoubeidi, Amina ^a  

^a VANCOUVER PROSTATE CENTRE   (Canada)

Author keywords

EGF; EMT; Hsp27; Prostate cancer; catenin

Indexed keywords

BETA CATENIN; EPIDERMAL GROWTH FACTOR; FIBRONECTIN; GLYCOGEN SYNTHASE KINASE 3BETA; HEAT SHOCK PROTEIN 27; MATRIX METALLOPROTEINASE; PROTEIN KINASE B; TRANSCRIPTION FACTOR SLUG; TYROSINE; UVOMORULIN; VIMENTIN; CTNNB1 PROTEIN, HUMAN; GELATINASE B; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; HSPB1 PROTEIN, HUMAN; MMP9 PROTEIN, HUMAN; SNAIL FAMILY TRANSCRIPTION FACTORS; TRANSCRIPTION FACTOR;

ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CELL MIGRATION; CELL NUCLEUS; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HUMAN CELL; INTRACELLULAR TRANSPORT; METASTASIS; PROMOTER REGION; PROSTATE CANCER; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN TRANSPORT; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; TUMOR INVASION; UBIQUITINATION; ACTIVE TRANSPORT; CELL MOTION; GENETICS; MALE; METABOLISM; PATHOLOGY; PHYSIOLOGY; PROSTATE TUMOR; TUMOR CELL LINE;

ACTIVE TRANSPORT, CELL NUCLEUS; BETA CATENIN; CELL LINE, TUMOR; CELL MOVEMENT; EPIDERMAL GROWTH FACTOR; EPITHELIAL-MESENCHYMAL TRANSITION; GLYCOGEN SYNTHASE KINASE 3; HSP27 HEAT-SHOCK PROTEINS; HUMANS; MALE; MATRIX METALLOPROTEINASE 9; NEOPLASM INVASIVENESS; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; TRANSCRIPTION FACTORS;

EID: 84922215477     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29122     Document Type: Article

References (50)

1. Zoubeidi A, Zardan A, Wiedmann RM, et al. Hsp27 promotes insulin-like growth factor-I survival signaling in prostate cancer via p90Rsk-dependent phosphorylation and inactivation of BAD. Cancer Res 2010;70:2307-17.
2. Paul C, Manero F, Gonin S, et al. Hsp27 as a negative regulator of cytochrome C release. Mol Cell Biol 2002;22:816-34.
3. Lee JW, Kwak HJ, Lee JJ, Kim YN, Park MJ, Jung SE, Hong SI, Lee JH, Lee JS. HSP27 regulates cell adhesion and invasion via modulation of focal adhesion kinase and MMP-2 expression. Eur J Cell Biol 2008;87:377-87.
4. Di K, Wong YC, Wang X. Id-1 promotes TGF-beta1-induced cell motility through HSP27 activation and disassembly of adherens junction in prostate epithelial cells. Exp Cell Res 2007;313:3983-99.
5. Conroy SE, Sasieni PD, Amin V, et al. Antibodies to heat-shock protein 27 are associated with improved survival in patients with breast cancer. Br J Cancer 1998;77:1875-9.
6. Bubendorf L, Kolmer M, Kononen J, et al. Hormone therapy failure in human prostate cancer: analysis by complementary DNA and tissue microarrays. J Natl Cancer Inst 1999;91:1758-64.
7. Cornford PA, Dodson AR, Parsons KF, et al. Heat shock protein expression independently predicts clinical outcome in prostate cancer. Cancer Res 2000;60:7099-105.
8. Bruey JM, Paul C, Fromentin A, et al. Differential regulation of HSP27 oligomerization in tumor cells grown in vitro and in vivo. Oncogene 2000;19:4855-63.
9. Zoubeidi A, Gleave M. Small heat shock proteins in cancer therapy and prognosis. Int J Biochem Cell Biol 2012.
10. Shiota M, Bishop JL, Nip KM, et al. Hsp27 regulates epithelial mesenchymal transition, metastasis, and circulating tumor cells in prostate cancer. Cancer Res 2013;73:3109-19.
11. Fidler IJ. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer 2003;3:453-8.
12. Citri A, Yarden Y. EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol 2006;7:505-16.
13. Schroeder JA, Lee DC. Transgenic mice reveal roles for TGFalpha and EGF receptor in mammary gland development and neoplasia. J Mammary Gland Biol Neoplasia 1997;2:119-29.
14. Grant S, Qiao L, Dent P. Roles of ERBB family receptor tyrosine kinases, and downstream signaling pathways, in the control of cell growth and survival. Front Biosci 2002;7:d376-89.
15. Ahmed N, Maines-Bandiera S, Quinn MA, et al. Molecular pathways regulating EGF-induced epithelio-mesenchymal transition in human ovarian surface epithelium. Am J Physiol Cell Physiol 2006;290:C1532-42.
16. Traish AM, Morgentaler A. Epidermal growth factor receptor expression escapes androgen regulation in prostate cancer: a potential molecular switch for tumour growth. Br J Cancer 2009;101:1949-56.
17. Heinlein CA, Chang C. Androgen receptor in prostate cancer. Endocr Rev 2004;25:276-308.
18. Khoury H, Dankort DL, Sadekova S, et al. Distinct tyrosine autophosphorylation sites mediate induction of epithelial mesenchymal like transition by an activated ErbB-2/Neu receptor. Oncogene 2001;20:788-99.
19. Bolos V, Peinado H, Perez-Moreno MA, et al. The transcription factor Slug represses E-cadherin expression and induces epithelial to mesenchymal transitions: a comparison with Snail and E47 repressors. J Cell Sci 2003;116:499-511.
20. Hotz B, Arndt M, Dullat S, et al. Epithelial to mesenchymal transition: expression of the regulators snail, slug, and twist in pancreatic cancer. Clin Cancer Res 2007;13:4769-76.
21. Umbas R, Isaacs WB, Bringuier PP, et al. Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer. Cancer Res 1994;54:3929-33.
22. Umbas R, Schalken JA, Aalders TW, et al. Expression of the cellular adhesion molecule Ecadherin is reduced or absent in high-grade prostate cancer. Cancer Res 1992;52:5104-9.
23. Huber AH, Stewart DB, Laurents DV, et al. The cadherin cytoplasmic domain is unstructured in the absence of beta-catenin. A possible mechanism for regulating cadherin turnover. J Biol Chem 2001;276:12301-9.
24. Jamora C, DasGupta R, Kocieniewski P, et al. Links between signal transduction, transcription and adhesion in epithelial bud development. Nature 2003;422:317-22.
25. Holsken A, Gebhardt M, Buchfelder M, et al. EGFR signaling regulates tumor cell migration in craniopharyngiomas. Clin Cancer Res 2011;17:4367-77.
26. Lee CH, Hung HW, Hung PH, et al. Epidermal growth factor receptor regulates beta-catenin location, stability, and transcriptional activity in oral cancer. Mol Cancer 2010;9:64.
27. Zoubeidi A, Zardan A, Beraldi E, et al. Cooperative interactions between androgen receptor (AR) and heat-shock protein 27 facilitate AR transcriptional activity. Cancer Res 2007;67:10455-65.
28. Gavert N, Ben-Ze'ev A. beta-Catenin signaling in biological control and cancer. J Cell Biochem 2007;102:820-8.
29. Fanelli MA, Montt-Guevara M, Diblasi AM, et al. P-cadherin and beta-catenin are useful prognostic markers in breast cancer patients; beta-catenin interacts with heat shock protein Hsp27. Cell Stress Chaperones 2008;13:207-20.
30. Kumano M, Furukawa J, Shiota M, et al. Cotargeting stress-activated hsp27 and autophagy as a combinatorial strategy to amplify endoplasmic reticular stress in prostate cancer. Mol Cancer Ther 2012;11:1661-71.
31. Parcellier A, Schmitt E, Gurbuxani S, et al. HSP27 is a ubiquitin-binding protein involved in I-kappaBalpha proteasomal degradation. Mol Cell Biol 2003;23:5790-802.
32. Yang W, Xia Y, Ji H, et al. Nuclear PKM2 regulates beta-catenin transactivation upon EGFR activation. Nature 2011;480:118-22.
33. Sanchez-Tillo E, de Barrios O, Siles L, et al. beta-catenin/TCF4 complex induces the epithelial-to-mesenchymal transition (EMT)-activator ZEB1 to regulate tumor invasiveness. Proc Natl Acad Sci USA 2011;108:19204-9.
34. Saegusa M, Hashimura M, Kuwata T, et al. Requirement of the Akt/beta-catenin pathway for uterine carcinosarcoma genesis, modulating E-cadherin expression through the transactivation of slug. Am J Pathol 2009;174:2107-15.
35. Xie D, Gore C, Liu J, et al. Role of DAB2IP in modulating epithelial-to-mesenchymal transition and prostate cancer metastasis. Proc Natl Acad Sci USA 2010;107:2485-90.
36. Gupta PB, Mani S, Yang J, et al. The evolving portrait of cancer metastasis. Cold Spring Harb Symp Quant Biol 2005;70:291-7.
37. Gan Y, Shi C, Inge L, et al. Differential roles of ERK and Akt pathways in regulation of EGFR-mediated signaling and motility in prostate cancer cells. Oncogene 2010;29:4947-58.
38. Kinkade CW, Castillo-Martin M, Puzio-Kuter A, et al. Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model. J Clin Invest 2008;118:3051-64.
39. Fang D, Hawke D, Zheng Y, et al. Phosphorylation of beta-catenin by AKT promotes beta-catenin transcriptional activity. J Biol Chem 2007;282:11221-9.
40. van Veelen W, Le NH, Helvensteijn W, et al. beta-catenin tyrosine 654 phosphorylation increases Wnt signalling and intestinal tumorigenesis. Gut 2011;60:1204-12.
41. Salomon DS, Brandt R, Ciardiello F, et al. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995;19:183-232.
42. Di Lorenzo G, Tortora G, D'Armiento FP, et al. Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer. Clin Cancer Res 2002;8:3438-44.
43. Festuccia C, Angelucci A, Gravina GL, et al. Epidermal growth factor modulates prostate cancer cell invasiveness regulating urokinase-type plasminogen activator activity. EGF-receptor inhibition may prevent tumor cell dissemination. Thromb Haemost 2005;93:964-75.
44. Foster CS, Dodson AR, Ambroisine L, et al. Hsp-27 expression at diagnosis predicts poor clinical outcome in prostate cancer independent of ETS-gene rearrangement. Br J Cancer 2009;101:1137-44.
45. de la Taille A, Rubin MA, Chen MW, et al. Beta-catenin-related anomalies in apoptosis-resistant and hormone-refractory prostate cancer cells. Clin Cancer Res 2003;9:1801-7.
46. Chen G, Shukeir N, Potti A, et al. Up-regulation of Wnt-1 and beta-catenin production in patients with advanced metastatic prostate carcinoma: potential pathogenetic and prognostic implications. Cancer 2004;101:1345-56.
47. Wan X, Liu J, Lu JF, et al. Activation of beta-catenin signaling in androgen receptor-negative prostate cancer cells. Clin Cancer Res 2012;18:726-36.
48. Horvath LG, Henshall SM, Lee CS, et al. Lower levels of nuclear beta-catenin predict for a poorer prognosis in localized prostate cancer. Int J Cancer 2005;113:415-22.
49. Whitaker HC, Girling J, Warren AY, et al. Alterations in beta-catenin expression and localization in prostate cancer. Prostate 2008;68:1196-205.
50. Bismar TA, Humphrey PA, Grignon DJ, et al. Expression of beta-catenin in prostatic adenocarcinomas: a comparison with colorectal adenocarcinomas. Am J Clin Pathol 2004;121:557-63.